Can a cancer drug tame tangled blood vessels?

NCT ID NCT07037238

Recruiting now Disease control Sponsor: Xuanwu Hospital, Beijing Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This Phase 2 trial tests the oral drug everolimus in 10 adults with vascular malformations—abnormal clusters of blood vessels. The goal is to see if the drug can shrink these lesions and reduce complications like bleeding. Participants take everolimus daily for up to a year, with MRI scans tracking changes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: everolimus (an oral drug that blocks a protein called mTOR)
What this could lead to: If it works, this could point toward a non-surgical treatment option for vascular malformations, potentially reducing lesion size and bleeding risk.
What could go wrong: This is a very small, early-phase trial with only 10 participants and no comparison group. The drug may not shrink lesions or could cause side effects like mouth sores, infections, or metabolic changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VASCULAR MALFORMATIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

vascular malformation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VASCULAR MALFORMATIONS

Contacts and locations

Locations

the Department of Neurosurgery, China International Neuroscience Institute, Xuanwu Hospital, Capital Medical University
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.